(2E,4Z,6E,8E,10E,12E,14E,16E,18E,20E,22E,24E)-2,6,10,14,19,23-hexamethyl-25-(2,6,6-trimethylcyclohexen-1-yl)pentacosa-2,4,6,8,10,12,14,16,18,20,22,24-dodecaenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4Z,6E,8E,10E,12E,14E,16E,18E,20E,22E,24E)-2,6,10,14,19,23-hexamethyl-25-(2,6,6-trimethylcyclohexen-1-yl)pentacosa-2,4,6,8,10,12,14,16,18,20,22,24-dodecaenoic acid
• 化学式: C₄₀H₅₂O₂
• 分子量: 564.8
• InChiKey: NESPPCWGYRQEJQ-YIKAQCKBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.3
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Arsenic trioxide for treatment of PIN1-associated disorders
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10980835B2

  公开（公告）日：2021-04-20

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.

  本发明涉及用三氧化二砷治疗Pin1相关疾病（例如，以Pin1活性升高为特征的疾病），可选择与维甲酸化合物联合使用。Pin1相关疾病可包括与Pin1活性异常水平相关的增殖性疾病（如癌症）、炎症和自身免疫性疾病等。
• ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US20180153934A1

  公开（公告）日：2018-06-07

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.